Etern Biopharma (shanghai) Co., Ltd.

Novartis Ag

Chinese Academy of Sciences

Shanghai Haihe Pharmaceutical Co., Ltd.

University of Pennsylvania

Qiangang Zheng

Jing Li

Jian Ding

Ming Xu

Hao Zhuge

Qinglong Zeng

Guoliang Xun

Qitao Xiao

Lei Du-Cuny

Feng He

Min Huang

Lei Liu

Lei Jiang

Meiyu Geng

Huixin Wan

Jianhua Cao

Shuai Tang

Jinbiao Liu

Xianlei Fu

Feifei Liu

Xiaojing Lan

Gregory Motz

Konstantinos John Mavrakias

Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.

Spiro aromatic ring compound and use thereof

Spiro aromatic ring compound and application thereof

Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2. 

Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof. In particular, provided in the present invention are the compound as shown in formula (I), a stereoisomer, a racemic body or a pharmaceutically acceptable salt thereof, and the use thereof in preparing drugs for preventing and treating diseases related to IDH mutation 

Compound having mutant IDH inhibitory activity, preparation method and use thereof

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R, R, R, R, and Rare as defined herein.

Substituted 5-cyanoindole compounds and uses thereof

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R, R, R, R, R, and Rare as defined herein.

Cyano-substituted indoles as LSD1 inhibitors

Growing community of inventors

Shanghai, China

Qiangang Zheng